Table 4.

Promising results that recommend non-coding RNAs as therapeutic targets for potential clinical applications.

Potential Role	Functional Studies	Research Model	Therapeutic Effect(s)	References
Targets for promising therapeutic strategies	Lentiviral overexpression of miR-200c	BRAFi-resistant cell lines	Restores sensitivity to BRAFi therapies	[124]
	Lipid nanoparticles loaded with miR-204-5p and/or miR-199b-5p	In vitro drug resistant models	Impair melanoma cell proliferation and viability Positively influence the effect of MAPKi	[154]
	siRNA-mediated knockdown of SPRY4-IT1	Malignant melanoma cell lines	Prevents tumour cell growth and limits invasion	[70,71]
	siRNA-mediated knockdown of HOTAIR		Inhibits cell motility and decreases invasion	[82]
	siRNA-mediated knockdown of UCA1		Inhibits cell proliferation and invasion Induces cell cycle arrest	[84]
	siRNA-mediated knockdown of MALAT1		Impairs melanoma cell migration	[83]
	siRNA-mediated knockdown of ANRIL		Diminishes colony formation and metastatic ability	[80]
	siRNA-mediated knockdown of SLNCR1		Decreases invasiveness of melanoma cells	[74]
	Lentiviral overexpression of GAS5	In vitro and in vivo models	Inhibits melanoma growth and cell migration	[86]
	SAMMSON-specific antisense oligonucleotide	Patient- derived xenograft	Induces apoptosis Exerts a synergistic anti-tumour effect with dabrafenib	[81]